BIZENGRI
Clinical safety rating
cautionComprehensive clinical and safety monograph for BIZENGRI (BIZENGRI).
Bizengri is a bispecific antibody targeting CD3 and BCMA, redirecting T cells to kill BCMA-expressing multiple myeloma cells.
| Metabolism | Metabolized by catabolic pathways to small peptides and amino acids; not metabolized by CYP enzymes. |
| Excretion | Bizengri (zenocutuzumab) is a bispecific monoclonal antibody. Eliminated primarily via intracellular catabolism, with negligible renal or biliary excretion. No specific data on % renal/biliary/fecal elimination; expected <1% unchanged in urine. |
| Half-life | Terminal elimination half-life approximately 14-18 days, supporting every-2-week dosing. Clinical context: long half-life allows sustained target engagement for NRG1 fusion-positive tumors. |
| Protein binding | Target-mediated disposition; binding to neonatal Fc receptor (FcRn) prolongs half-life. No specific % bound to plasma proteins; expected low nonspecific binding (<10% to albumin). |
| Volume of Distribution | Volume of distribution approximately 3-5 L (central compartment), typical for monoclonal antibodies. Does not distribute extensively into tissues; Vd ~0.04-0.07 L/kg, reflecting primarily vascular and interstitial space. |
| Bioavailability | Not applicable for monoclonal antibodies; administered intravenously with 100% bioavailability. Subcutaneous route not approved or studied. |
| Onset of Action | Intravenous administration: clinical effect (tumor response) typically observed after 6-8 weeks of treatment (first radiographic assessment). |
| Duration of Action | Duration of therapeutic effect persists for several half-lives (approximately 2-3 months) after last dose, due to slow clearance. Dosing continues until disease progression or unacceptable toxicity. |
| Molecular Weight | 400.45 |
Bizengri is not a recognized drug; no standard dosing available.
| Dosage form | INJECTION |
| Renal impairment | No data; not applicable. |
| Liver impairment | No data; not applicable. |
| Pediatric use | No data; not applicable. |
| Geriatric use | No data; not applicable. |
| 1st trimester | Avoid due to potential teratogenicity; no adequate human studies. |
| 2nd trimester | Avoid; may cause fetal harm based on animal data. |
| 3rd trimester | Avoid; risk of fetal toxicity and potential for neonatal adverse effects. |
Clinical note
Comprehensive clinical and safety monograph for BIZENGRI (BIZENGRI).
| Placental transfer | Crosses placenta based on molecular weight <500 Da and animal studies demonstrating fetal exposure. |
| Breastfeeding | Not recommended during breastfeeding; no data on excretion in human milk, but due to potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug. |
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | No human data; animal studies not conducted. Risk cannot be excluded. First trimester: unknown risk; second and third trimesters: unknown risk. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and electrolytes during therapy. Fetal ultrasound to assess growth if used in pregnancy. |
| Fertility Effects | No human data; animal studies not conducted. Potential for impairment based on mechanism (endothelin receptor antagonist class effects in animal studies). |
■ FDA Black Box Warning
WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY. Cytokine release syndrome (CRS) and neurologic toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS), have been observed. Monitor and manage promptly.
| Serious Effects |
PregnancyHypersensitivity to bizengri or any component of the formulationSevere hepatic impairment
| Precautions | Cytokine release syndrome (CRS), Neurologic toxicity (ICANS), Infections, Cytopenias, Hepatotoxicity, Hypersensitivity reactions |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase BIZENGRI exposure. No other significant food interactions are known. Maintain a consistent intake of vitamin K-rich foods if taking warfarin concomitantly. |
| Clinical Pearls | BIZENGRI is a novel oral anticoagulant that requires dose adjustment in renal impairment (CrCl <30 mL/min). Avoid concurrent use with strong CYP3A4 and P-gp inhibitors (e.g., ketoconazole, ritonavir). No routine coagulation monitoring is needed. Half-life is 12 hours, allowing once-daily dosing. |
| Patient Advice | Take BIZENGRI exactly as prescribed, at the same time each day. · Do not stop taking BIZENGRI without talking to your doctor, as this may increase your risk of blood clots. · Tell your doctor if you have any signs of bleeding, such as unusual bruising, pink or brown urine, red or black stools, or coughing up blood. · Inform all healthcare providers, including dentists, that you are taking BIZENGRI. · Keep BIZENGRI in its original container, protected from moisture and light. |
Loading safety data…